Juq-063 - ((full))

appears in academic guidelines related to Intermittent Fasting

Stay tuned for upcoming Phase IIb results (expected Q2 2027) and further updates on combination strategies. JUQ-063

Ready to explore how JUQ-063 can empower your region? Connect with NovaTech to learn about pilot programs and partnerships. Let’s build a sustainable future—together. Let’s build a sustainable future—together

| Agency | Pathway | Anticipated Milestones | |--------|---------|------------------------| | | Fast Track (granted 2025) → Breakthrough Therapy (expected Q1 2026) | NDA submission targeted Q2 2028 (assuming Phase III positive). | | EMA (EU) | PRIority Medicines (PRIME) designation (granted 2025) | MAA filing Q3 2028. | | PMDA (Japan) | Sakigake (early‑access) designation under review | Submission 2028. | | | PMDA (Japan) | Sakigake (early‑access) designation

One hypothesis, put forward by the Institute for Quantum Materials in Zurich, suggests that JUQ‑063 designates a specific topological qubit architecture. Topological qubits exploit non‑abelian anyons—quasiparticles whose exchange operations (braiding) form the basis of fault‑tolerant quantum computation. The “JUQ” could be an acronym for , a research group that, in 2035, reported a prototype where superconducting nanowires intersected with semiconducting quantum dots to host Majorana zero modes. The “063” could then refer to a particular braiding sequence (six operations, three of which are nontrivial) that yields a universal gate set.